Literature DB >> 11529668

Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo.

V W Lui1, L D Falo, L Huang.   

Abstract

BACKGROUND: IL-12 is a potent antitumor cytokine for cancer gene therapy. Previously, we demonstrated that single systemic administration of naked DNA (encoding IL-12) could serve as a good model for in vivo evaluation of the antitumor effect of a candidate gene (unpublished data). In the present study, we propose that this gene delivery method could be a very useful model for in vivo evaluation of the toxicity of a given therapeutic gene (using IL-12 as an example). By comparing the toxicities and the effects of initial IL-12 administration on subsequent transgene expression, both IL-12 gene delivery and recombinant murine IL-12 protein (rmIL-12) administration showed similar toxicity profiles.
METHODS: Naked DNA encoding murine IL-12 (mIL-12) was delivered into mice by systemic administration. Toxicity profiles of mice treated with DNA or rmIL-12 were compared.
RESULTS: Systemic administration of naked DNA encoding mIL-12 resulted in very similar toxicity as rmIL-12 with respect to liver enzyme, hematological and immunological profiles. Repeated injection of mIL-12 gene did not recover a high level of mIL-12 production as the first injection. Moreover, initial mIL-12 administration resulted in inhibition of subsequent reporter gene expression with both viral and non-viral promoters (CMV, human alpha-antitrypsin or chicken beta-actin promoter). This transgene inhibition effect was entirely mediated by IFN-gamma as the transgene expression was fully recovered in IFN-gamma knockout mice.
CONCLUSIONS: Systemic IL-12 therapy, with either a protein or gene therapy approach, resulted in comparable liver and systemic toxicities. Refractoriness of mIL-12 production by subsequent administration of mIL-12 gene was observed. The transgene attenuation effect of IL-12 pre-dosing (either by IL-12 or rmIL-12), mediated by IFN-gamma, provided important insights for the design of IL-12 combination gene therapy and the improvement of gene vectors for IL-12 therapy. The present results show that simple injection of naked DNA could serve as a good model for in vivo evaluation of the toxicity of a candidate therapeutic gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529668     DOI: 10.1002/jgm.201

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  11 in total

Review 1.  The promise of gene therapy in gastrointestinal and liver diseases.

Authors:  J Prieto; M Herraiz; B Sangro; C Qian; G Mazzolini; I Melero; J Ruiz
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

2.  Intranasal coadministration of live lactococci producing interleukin-12 and a major cow's milk allergen inhibits allergic reaction in mice.

Authors:  Naima G Cortes-Perez; Sandrine Ah-Leung; Luis G Bermúdez-Humarán; Gérard Corthier; Jean-Michel Wal; Philippe Langella; Karine Adel-Patient
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

3.  Identification of infected B-cell populations by using a recombinant murine gammaherpesvirus 68 expressing a fluorescent protein.

Authors:  Christopher M Collins; Jeremy M Boss; Samuel H Speck
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

Review 4.  Gene therapy: regulations, ethics and its practicalities in liver disease.

Authors:  Xi Jin; Yi-Da Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

Review 5.  Exosomes and their Application in Biomedical Field: Difficulties and Advantages.

Authors:  Jafar Rezaie; Saeed Ajezi; Çığır Biray Avci; Mohammad Karimipour; Mohammad Hossein Geranmayeh; Alireza Nourazarian; Emel Sokullu; Aysa Rezabakhsh; Reza Rahbarghazi
Journal:  Mol Neurobiol       Date:  2017-05-11       Impact factor: 5.590

6.  Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer.

Authors:  Lucia Vanrell; Marianna Di Scala; Laura Blanco; Itziar Otano; Irene Gil-Farina; Victor Baldim; Astrid Paneda; Pedro Berraondo; Stuart G Beattie; Abdelwahed Chtarto; Lilianne Tenenbaum; Jesús Prieto; Gloria Gonzalez-Aseguinolaza
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

7.  Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity.

Authors:  Maria Cecilia Rodriguez-Galan; Della Reynolds; Silvia G Correa; Pablo Iribarren; Morihiro Watanabe; Howard A Young
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

8.  Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production.

Authors:  Luis G Bermúdez-Humarán; Philippe Langella; Naima G Cortes-Perez; Alexandra Gruss; Reyes S Tamez-Guerra; Sergio C Oliveira; Odila Saucedo-Cardenas; Roberto Montes de Oca-Luna; Yves Le Loir
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

9.  Limited expression of non-integrating CpG-free plasmid is associated with increased nucleosome enrichment.

Authors:  Omar Habib; Rozita Mohd Sakri; Nadiah Ghazalli; De-Ming Chau; King-Hwa Ling; Syahril Abdullah
Journal:  PLoS One       Date:  2020-12-21       Impact factor: 3.240

10.  Abrogation of TNFα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12.

Authors:  Bibiana Barrios; Natalia S Baez; Della Reynolds; Pablo Iribarren; Hugo Cejas; Howard A Young; Maria Cecilia Rodriguez-Galan
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.